文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

侵袭性B细胞非霍奇金淋巴瘤患者接受嵌合抗原受体T细胞治疗后的晚期不良事件

Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.
PubMed 文献 · JAMA Netw Open · 2025-02-03
一句话结论接受CD19 CAR-T治疗的复发/难治性LBCL患者中,78.5%发生至少1次晚期不良事件,感染最常见且持续稳定,非复发死亡均与感染相关。

这项前瞻性观察性临床实践队列研究纳入2018年9月1日至2022年12月31日西班牙6家医院的172例接受CD19 CAR-T(替沙仑赛或阿基仑赛)治疗且输注后存活至少3个月的复发/难治性LBCL成人患者。晚期不良事件发生率为78.5%,感染发生率最高(5.6/100人月),其次为中性粒细胞减少(3.6/100人月)和血小板减少(2.2/100人月)。感染在整个研究期间保持稳定,而血细胞减少在输注6个月后下降。所有非复发相关死亡均归因于感染。作者认为CAR-T安全性良好,但需持续随访,因严重不良事件可在输注数年后发生。

要点

  • 172例接受CD19 CAR-T后存活≥3个月的LBCL患者中,135例(78.5%)发生至少1次任何级别的晚期不良事件。
  • 感染是最常见的晚期不良事件,发生率为5.6/100人月(95%CI 4.5-7.0),且在整个研究期间保持稳定。
  • 中性粒细胞减少发生率为3.6/100人月(95%CI 2.9-4.5),血小板减少为2.2/100人月(95%CI 1.7-3.0),血细胞减少在输注6个月后下降。
  • 所有非复发相关死亡均由感染导致:COVID-19肺炎3例,脓毒症或细菌性肺炎4例(共7例)。
  • 皮肤不良事件27例次(23例,13.4%)均为轻度,其中88.9%(24/27)在输注3个月后开始;神经系统不良事件15例次(15例,8.7%),心血管不良事件13例次(10例,5.8%)。

适用人群与场景

  • 成人(平均[SD]年龄58.5[13.7]岁;男性101例[58.7%])复发或难治性大B细胞淋巴瘤(LBCL)患者。
  • 接受商业可及的CD19靶向CAR-T细胞(替沙仑赛或阿基仑赛)治疗,且输注后存活至少3个月、未接受后续抗淋巴瘤治疗。
  • 研究在西班牙6家医院进行,为临床实践队列。

诊断标准与关键阈值

  • 晚期不良事件定义为输注后第3个月开始收集的新发不良事件,或此前发生但至该时间点仍持续存在的不良事件。
  • 数据收集截至患者接受新的抗淋巴瘤治疗、失访、死亡或输注后24个月,以先发生者为准。

红旗征与不能漏的情况

  • 感染是晚期最常见不良事件(5.6/100人月,95%CI 4.5-7.0),且整个研究期间发生率稳定,所有非复发相关死亡均由感染导致(COVID-19肺炎3例,脓毒症或细菌性肺炎4例)。
  • 血细胞减少(中性粒细胞减少3.6/100人月,95%CI 2.9-4.5;血小板减少2.2/100人月,95%CI 1.7-3.0)在输注6个月后下降,但仍需关注。
  • 晚期不良事件还包括皮肤事件(23例,13.4%,均为轻度)、神经系统事件(15例,8.7%)和心血管事件(10例,5.8%)。
  • 继发性肿瘤5例(4例,2.3%),未观察到T细胞恶性肿瘤。

研究设计与关键结果

  • 研究类型为前瞻性观察性临床实践队列研究,纳入172例患者,来自6家西班牙医院,接受替沙仑赛或阿基仑赛治疗。
  • 主要结局:135例(78.5%)发生至少1次任何级别的晚期不良事件;感染发生率5.6/100人月(95%CI 4.5-7.0),中性粒细胞减少3.6/100人月(95%CI 2.9-4.5),血小板减少2.2/100人月(95%CI 1.7-3.0)。
  • 感染发生率在整个研究期间保持稳定,血细胞减少在输注6个月后下降。
  • 非复发相关死亡均因感染:COVID-19肺炎3例,脓毒症或细菌性肺炎4例。
  • 皮肤不良事件:23例(13.4%)发生27例次,均为轻度,88.9%(24/27)在输注3个月后开始。
  • 神经系统不良事件:15例(8.7%)发生15例次;心血管不良事件:10例(5.8%)发生13例次;继发性肿瘤:4例(2.3%)发生5例,无T细胞恶性肿瘤。

证据类型、等级与局限

  • 证据类型:前瞻性观察性临床实践队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为CAR-T细胞疗法安全性良好,但需要持续随访患者,因为严重不良事件可能在输注数年后发生。
  • 对接受CD19 CAR-T治疗后存活≥3个月的患者,应警惕感染(最常见且持续稳定)及血细胞减少(6个月后下降),并注意皮肤、神经、心血管不良事件和继发性肿瘤。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Acute adverse events (AEs) after chimeric antigen receptor (CAR) T-cell infusion are well documented, but less information is available regarding the long-term toxic effects.

OBJECTIVE: To assess the occurrence of late AEs for adult patients with large B-cell lymphoma (LBCL) treated with commercially available CD19-targeted CAR T cells.

DESIGN, SETTING, AND PARTICIPANTS: A prospective, observational, clinical practice cohort study was conducted from September 1, 2018, to December 31, 2022, among 172 adult patients in 6 Spanish hospitals who received CD19-targeted CAR T-cell therapy for relapsed or refractory LBCL and survived at least 3 months after infusion, without subsequent antilymphoma therapy.

EXPOSURE: Treatment with tisagenlecleucel or axicabtagene ciloleucel.

MAIN OUTCOMES AND MEASURES: Data on any late AEs occurring in this patient population were collected until the patients received new antilymphoma therapy, were lost to follow-up, died, or reached 24 months after infusion, whichever occurred first. Data collection for each patient started at the third month after infusion and included new-onset AEs, as well as persistent AEs that started earlier but were still ongoing at that time point.

RESULTS: The study enrolled 172 patients (mean [SD] age, 58.5 [13.7] years; 101 men [58.7%]), of whom 135 (78.5%) experienced at least 1 late AE of any grade. Infections were the late AEs with the highest incidence (5.6 per 100 person-months [95% CI, 4.5-7.0 per 100 person-months]), followed by neutropenia (3.6 per 100 person-months [95% CI, 2.9-4.5 per 100 person-months]) and thrombocytopenia (2.2 per 100 person-months [95% CI, 1.7-3.0 per 100 person-months]). The incidence of infectious episodes remained stable during the whole study period, while cytopenias decreased beyond 6 months after infusion. All cases of nonrelapse-related mortality were due to infections (COVID-19 pneumonia in 3 patients and sepsis or bacterial pneumonia in 4 patients). Twenty-three patients (13.4%) experienced 27 dermatologic AEs, all mild, with most of them (88.9% [24 of 27]) starting beyond 3 months after infusion. Fifteen neurologic AEs were reported in 15 patients (8.7%), and 10 patients (5.8%) developed 13 cardiovascular AEs. Five secondary neoplasms were reported in 4 patients (2.3%), with no cases of T-cell malignant neoplasms.

CONCLUSIONS AND RELEVANCE: This cohort study suggests that CAR T-cell therapy has a favorable safety profile. However, continuous follow-up of patients is needed, as serious AEs can occur years after infusion.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Camacho-Arteaga L, Iacoboni G, Kwon M, et al. Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma. JAMA Netw Open. 2025. PMID: 39998830. doi:10.1001/jamanetworkopen.2024.61683

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。